- Disease: Respiratory syncytial virus infection
- Study type: Observational Cohort Study, Prevention
- Study type descriptors: Prospective, Single centre
- Objective: To determine the effect of nirsevimab immunization on the development of the infant’s own humoral immune response (antibody levels) after an RSV infection
- Number of participants enrolled: Enrollment ongoing
- Study enrolling from
- Study includes follow-up for 12 months
Study Data
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
External Links
Other information
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to